Ionis Pharmaceuticals received FDA approval for Dawnzera (donidalorsen), an antisense RNA therapy designed to prevent attacks in patients with hereditary angioedema (HAE), a rare genetic disorder marked by life-threatening swelling episodes. Dawnzera offers a prophylactic treatment, administered through a convenient autoinjector, potentially improving patient adherence and outcomes. Ionis aims to switch patients dissatisfied with existing therapies to Dawnzera, highlighting its competitive pricing and flexible dosing schedule. This approval marks Ionis' second FDA-approved drug within a year, bolstering its portfolio in rare disease therapeutics.